ABSTRACT
Insulin-like growth factor 1 (IGF-1) is the final pathway of the growth hormone cascade, and is a better clinical measure of acromegaly than growth hormone itself. In patients with acromegaly, medical treatment w i t h a somatostatin analog normalizes growth hormone and IGF-1 levels and produces clinical improvement quickly.
Footnotes
↵* Dr. Barkan’s lecture was sponsored by Novartis Pharmaceuticals Corporation.
- Copyright © 1998 The Cleveland Clinic Foundation. All Rights Reserved.